INSR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of INSR. The page also collects GeneMedi's different modalities and formats products for INSR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the INSR target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a member of the receptor tyrosine kinase family of proteins. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that form a heterotetrameric receptor. Binding of insulin or other ligands to this receptor activates the insulin signaling pathway, which regulates glucose uptake and release, as well as the synthesis and storage of carbohydrates, lipids and protein. Mutations in this gene underlie the inherited severe insulin resistance syndromes including type A insulin resistance syndrome, Donohue syndrome and Rabson-Mendenhall syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2015]
|Gene Official Name||INSR|
|Gene Alias||CD220, HHF5|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index|
Pre-made INSR-specific INN-index biosimilar (antibody&conjugates)-insulin efsitora alfa, valanafusp alfa, insulin, Valanafusp
Anti-INSR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-INN-870||Pre-Made Insulin Efsitora Alfa Biosimilar, Fusion Protein targeting INSR fused with human IGHG2 Fc (Fragment constant): Recombinant therapeutic protein targeting CD220/HHF5||insulin efsitora alfa||INSR||Fusion Protein|
|GMP-Bios-INN-1043||Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5||valanafusp alfa||INSR||Fusion Protein|
|GMP-Bios-INN-869||Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5||insulin||INSR||Recombinant Protein|
|GMP-Bios-ab-608||Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody||Valanafusp||INSR||Whole mAb Fusion|
Pre-made anti-INSR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-INSR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-INSR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T85435-Ab||Anti-INSR monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|